all these are looking ripe for this week
ams ,dcd,hti,rgo,hrd,goal,ubc,and of course smith@nephew,slough estates,hawtins plc,hsbc,3ii,ng,sse,dsg. tips for the week free!!!!!!!!!!!!!!1

Final Results.

Q4 Highlights

· Revenue $1,106 million, up 4% on a reported and 3% on an underlying basis
· Trading profit was $279 million
· Trading profit margin of 25.2%, exceeding Q4 expectation of 24%
· Orthopaedics delivered significant improvement in profitability quarter-on-quarter
· Endoscopy delivered good revenue growth and excellent trading profit margin
· Advanced Wound Management grew at more than twice the market rate
· EPSA was up at 21.9¢
· Proposed final dividend up 10% to 10.8 cents per share

Full Year Commentary

· Reported revenue of $4,270 million, up 8% on a reported and 4% on an underlying basis
· Reported trading profit was $961 million
· Trading margin 22.5%
· EPSA increased 1.2% to 74.5¢
· Strong cash generation, net debt reduced by $354 million to $138 million

Half Yearly Report

Q2 Financial Highlights
· Revenue of $1,029 million, up 2% on an underlying basis
· Trading profit of $234 million, up 6% on an underlying basis
· Trading profit margin up 80 bps to 22.7% as ASD restructuring benefits come through
· Strong performance from Sports Medicine Joint Repair and NPWT
· EPSA consistent at 18.1 cents
· Group moves to net cash of $150 million
· Interim dividend increased 50% to 9.9¢ and new progressive dividend policy

Smith & Nephew completes Healthpoint acquisition

Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology business, today announces the completion of the acquisition of substantially all the assets of Healthpoint Biotherapeutics ("Healthpoint"). The purchase price of $782 million in cash has been financed from Smith & Nephew's existing cash resources and bank facilities.

The acquisition gives Smith & Nephew a strong position in bioactives, the fastest growing area of advanced wound management.

Smith & Nephew said its full year profits to be at the lower end of its guided range after a third quarter where growth was flat outside US and emerging markets but its artificial hips business returned to growth. Revenue grew 3% to $1.15bn in the three months to 30 September, leading management to expect underlying revenue growth for the full year to be at the lower end of the 3-4% guided range, with profit margins to be at the lower end of the guided 20-70 basis points range.